Skip to content

Study · Systematic review · 2026

8 results

Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Sebastian SA, Ayyalu T, Bimal T, Patel B, Kittleson MM, Carbone S, Yehya A

Disease-a-month : DM19 Mar 2026

PMID41862384 (opens in a new tab)DOI10.1016/j.disamonth.2026.102099 (opens in a new tab)PepBankPUB-41862384
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with HFpEF and obesity, tirzepatide was associated with a lower risk of cardiovascular mortality or worsening heart failure events than standard therapy.

    In plain wordsIn people with obesity and HFpEF, tirzepatide was linked to fewer cardiovascular deaths or worsening heart failure events than standard therapy.

    Peptide
    Tirzepatide
    Outcome
    DecreaseComposite of cardiovascular mortality and worsening heart failure events
    Study

    n: not reported in source

    Comparator
    Standard therapy
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.5 ratio
    vs standard therapy

    Source sentences

    Summary
    Tirzepatide was associated with a significant reduction in the composite outcome of cardiovascular mortality and worsening heart failure events compared with standard therapy (HR 0.50; 95% CI: 0.42-0.60; p < 0.001).
    1 context sentence
    Summary · context
    Our final analysis included five studies, including RCTs and observational studies with a total of 47,710 patients with HFpEF and BMI ≥ 30 kg/m2, a mean age of 64.7 years, and follow-up ranging from 52 to 146 weeks.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with HFpEF and obesity, tirzepatide was associated with fewer heart failure exacerbation events than standard therapy.

    In plain wordsIn people with obesity and HFpEF, tirzepatide was linked to fewer heart failure exacerbations than standard therapy.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHeart failure exacerbation events
    Study

    n: not reported in source

    Comparator
    Standard therapy
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.75 ratio
    vs standard therapy

    Source sentences

    Summary
    A significant reduction in heart failure exacerbation events alone was also observed with tirzepatide versus standard therapy (HR 0.75; p = 0.04)
    1 context sentence
    Summary · context
    Our final analysis included five studies, including RCTs and observational studies with a total of 47,710 patients with HFpEF and BMI ≥ 30 kg/m2, a mean age of 64.7 years, and follow-up ranging from 52 to 146 weeks.
  3. 03HumanSystematic reviewEfficacy outcome

    In patients with HFpEF and obesity, heart failure exacerbation events did not differ significantly between tirzepatide and semaglutide.

    In plain wordsIn people with obesity and HFpEF, tirzepatide and semaglutide did not differ significantly in heart failure exacerbations.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHeart failure exacerbation events
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.95 ratio
    vs semaglutide

    Source sentences

    Summary
    whereas no significant difference was seen when compared with semaglutide (HR 0.95; p = 0.31)
    1 context sentence
    Summary · context
    Our final analysis included five studies, including RCTs and observational studies with a total of 47,710 patients with HFpEF and BMI ≥ 30 kg/m2, a mean age of 64.7 years, and follow-up ranging from 52 to 146 weeks.
  4. 04HumanSystematic reviewEfficacy outcome

    In patients with HFpEF and obesity, heart failure hospitalization did not differ significantly between tirzepatide and standard therapy.

    In plain wordsIn people with obesity and HFpEF, tirzepatide and standard therapy did not differ significantly in heart failure hospital stays.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHeart failure hospitalization
    Study

    n: not reported in source

    Comparator
    Standard therapy
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Heart failure hospitalization and all-cause mortality did not differ significantly between tirzepatide and either standard therapy or semaglutide.
    1 context sentence
    Summary · context
    Our final analysis included five studies, including RCTs and observational studies with a total of 47,710 patients with HFpEF and BMI ≥ 30 kg/m2, a mean age of 64.7 years, and follow-up ranging from 52 to 146 weeks.
  5. 05HumanSystematic reviewEfficacy outcome

    In patients with HFpEF and obesity, heart failure hospitalization did not differ significantly between tirzepatide and semaglutide.

    In plain wordsIn people with obesity and HFpEF, tirzepatide and semaglutide did not differ significantly in heart failure hospital stays.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHeart failure hospitalization
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Heart failure hospitalization and all-cause mortality did not differ significantly between tirzepatide and either standard therapy or semaglutide.
    1 context sentence
    Summary · context
    Our final analysis included five studies, including RCTs and observational studies with a total of 47,710 patients with HFpEF and BMI ≥ 30 kg/m2, a mean age of 64.7 years, and follow-up ranging from 52 to 146 weeks.
  6. 06HumanSystematic reviewEfficacy outcome

    In patients with HFpEF and obesity, all-cause mortality did not differ significantly between tirzepatide and standard therapy.

    In plain wordsIn people with obesity and HFpEF, tirzepatide and standard therapy did not differ significantly in deaths from any cause.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAll-cause mortality
    Study

    n: not reported in source

    Comparator
    Standard therapy
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Heart failure hospitalization and all-cause mortality did not differ significantly between tirzepatide and either standard therapy or semaglutide.
    1 context sentence
    Summary · context
    Our final analysis included five studies, including RCTs and observational studies with a total of 47,710 patients with HFpEF and BMI ≥ 30 kg/m2, a mean age of 64.7 years, and follow-up ranging from 52 to 146 weeks.
  7. 07HumanSystematic reviewEfficacy outcome

    In patients with HFpEF and obesity, all-cause mortality did not differ significantly between tirzepatide and semaglutide.

    In plain wordsIn people with obesity and HFpEF, tirzepatide and semaglutide did not differ significantly in deaths from any cause.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAll-cause mortality
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Heart failure hospitalization and all-cause mortality did not differ significantly between tirzepatide and either standard therapy or semaglutide.
    1 context sentence
    Summary · context
    Our final analysis included five studies, including RCTs and observational studies with a total of 47,710 patients with HFpEF and BMI ≥ 30 kg/m2, a mean age of 64.7 years, and follow-up ranging from 52 to 146 weeks.
  8. 08HumanSystematic reviewSafety outcome

    In patients with HFpEF and obesity, adverse drug reactions did not differ significantly with tirzepatide in the pooled analysis.

    In plain wordsIn people with obesity and HFpEF, tirzepatide did not cause significantly more adverse drug reactions in the pooled analysis.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAdverse drug reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No statistically significant difference in adverse drug reactions was observed.
    1 context sentence
    Summary · context
    Our final analysis included five studies, including RCTs and observational studies with a total of 47,710 patients with HFpEF and BMI ≥ 30 kg/m2, a mean age of 64.7 years, and follow-up ranging from 52 to 146 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.